AU2021352146A1 - Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders - Google Patents

Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders Download PDF

Info

Publication number
AU2021352146A1
AU2021352146A1 AU2021352146A AU2021352146A AU2021352146A1 AU 2021352146 A1 AU2021352146 A1 AU 2021352146A1 AU 2021352146 A AU2021352146 A AU 2021352146A AU 2021352146 A AU2021352146 A AU 2021352146A AU 2021352146 A1 AU2021352146 A1 AU 2021352146A1
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
formula
ampk
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021352146A
Other languages
English (en)
Other versions
AU2021352146A9 (en
Inventor
Thomas Edlund
Jacob Westman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagenon AB
Original Assignee
Betagenon AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagenon AB filed Critical Betagenon AB
Publication of AU2021352146A1 publication Critical patent/AU2021352146A1/en
Assigned to BETAGENON AB reassignment BETAGENON AB Amend patent request/document other than specification (104) Assignors: BETAGENON BIO AB
Publication of AU2021352146A9 publication Critical patent/AU2021352146A9/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/65392—Five-membered rings containing two nitrogen atoms
    • C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021352146A 2020-10-01 2021-09-30 Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders Pending AU2021352146A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2015585.9A GB202015585D0 (en) 2020-10-01 2020-10-01 New compounds
GB2015585.9 2020-10-01
PCT/GB2021/052535 WO2022069894A1 (en) 2020-10-01 2021-09-30 Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders

Publications (2)

Publication Number Publication Date
AU2021352146A1 true AU2021352146A1 (en) 2023-06-01
AU2021352146A9 AU2021352146A9 (en) 2025-01-16

Family

ID=73223766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021352146A Pending AU2021352146A1 (en) 2020-10-01 2021-09-30 Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders

Country Status (13)

Country Link
US (1) US12643918B2 (cg-RX-API-DMAC7.html)
EP (1) EP4222147B1 (cg-RX-API-DMAC7.html)
JP (1) JP7793614B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230079163A (cg-RX-API-DMAC7.html)
CN (1) CN116368141B (cg-RX-API-DMAC7.html)
AU (1) AU2021352146A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193947A1 (cg-RX-API-DMAC7.html)
ES (1) ES3018732T3 (cg-RX-API-DMAC7.html)
GB (1) GB202015585D0 (cg-RX-API-DMAC7.html)
HU (1) HUE071685T2 (cg-RX-API-DMAC7.html)
MX (1) MX2023003825A (cg-RX-API-DMAC7.html)
PL (1) PL4222147T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022069894A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202112529D0 (en) * 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
JPWO2024075784A1 (cg-RX-API-DMAC7.html) * 2022-10-05 2024-04-11

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010270030B2 (en) 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
WO2020095010A1 (en) * 2018-11-05 2020-05-14 Balticgruppen Bio Ab Methods of treating diabetes in severe insulin-resistant diabetic subjects
GB201915094D0 (en) 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
ES3075388T3 (en) 2019-10-18 2026-08-04 Betagenon Ab New formulations
GB202015585D0 (en) 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
GB202112529D0 (en) 2021-09-02 2021-10-20 Betagenon Bio Ab New compounds
CN122421964A (zh) 2023-07-20 2026-07-17 塔吉农有限责任公司 使用双重ampk激活剂和线粒体解偶联剂调节血糖水平的方法
JP2026526085A (ja) 2023-07-20 2026-08-05 ベタゲノン アーベー 代謝非柔軟性により誘発される心筋症の治療方法
CN121925257A (zh) 2023-08-03 2026-04-24 塔吉农有限责任公司 用pdk抑制剂4-氯-n-(2-(4-氯苄基)-3-氧代-2,3-二氢-1,2,4-噻二唑-5-基)苯甲酰胺治疗癌症
WO2025252672A1 (en) 2024-06-03 2025-12-11 Betagenon Ab Use of tryptophan and metabolites thereof as biomarkers for treatment methods

Also Published As

Publication number Publication date
ES3018732T3 (en) 2025-05-19
GB202015585D0 (en) 2020-11-18
MX2023003825A (es) 2023-06-06
PL4222147T3 (pl) 2025-06-09
EP4222147B1 (en) 2025-03-19
CN116368141A (zh) 2023-06-30
HUE071685T2 (hu) 2025-09-28
JP2023543924A (ja) 2023-10-18
CA3193947A1 (en) 2022-04-07
KR20230079163A (ko) 2023-06-05
US12643918B2 (en) 2026-06-02
WO2022069894A1 (en) 2022-04-07
JP7793614B2 (ja) 2026-01-05
EP4222147A1 (en) 2023-08-09
EP4222147C0 (en) 2025-03-19
US20230382930A1 (en) 2023-11-30
CN116368141B (zh) 2025-09-23

Similar Documents

Publication Publication Date Title
EP4222147B1 (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
US6706746B2 (en) Thiazolidine-2,4-dione hydrochloride salt, pharmaceutical compositions thereof and treatment method therewith
US20230109134A1 (en) Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof
JP4115105B2 (ja) ピラゾール誘導体
US20250136563A1 (en) Thiadiazolone derivatives useful as ampk activator
AU2019360446A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
US20240082222A1 (en) 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine
JP7474869B2 (ja) ピリミジンシクロヘキシルグルココルチコイド受容体モジュレーターの製剤
EP4585593A1 (en) Polymorph of glp-1r agonist compound, preparation method therefor, and use thereof
JP7261349B2 (ja) ピリミジン-5-カルボキサミド化合物
HK40092998A (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
HK40092998B (en) Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders
CN111662239B (zh) 1,2,4-三唑类化合物及其制法和药物用途
JP2001158789A (ja) 4,5,6,7−テトラヒドロチエノ〔2,3−c〕ピリジン誘導体
CN106432026A (zh) 一类对糖尿病具有潜在治疗活性的化合物
WO2008047769A1 (en) Glucose metabolism ameliorating agent
JP6843845B2 (ja) 1,4−ジ−(4−メチルチオフェニル)−3−フタロイルアゼチジン−2−オンおよびその誘導体
WO2010098298A1 (ja) 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物
WO2025099561A1 (en) Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
EA051917B1 (ru) Новая соль соединения-агониста рецептора гпп-1, способ ее получения и содержащая ее фармацевтическая композиция
JPWO1993023360A1 (ja) 新規第4級アンモニウム塩類およびそれらの医薬としての使用

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: BETAGENON AB

Free format text: FORMER NAME(S): BETAGENON BIO AB

SREP Specification republished